Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Printable version of editorial staff

Dimitrios Roukos

Address: NEOCHOROPOULO P.O. BOX 267 , TK 45500 IOANNINA (Greece)
Telephone: +302651007423
Fax: +302651007094
Nationality: Greek
Date of birth: 31 March 1953


Education and training



1974 - 1980

Ptychion Iatrikis (Medical Diploma), University of Athens ( School of Medicine ) ysl outlet



1982 - 1983

Senior House Officer (Basic Surgery Specialty Training, University Hospital of Ioannina)

1983 - 1989

Postgraduate specialist training in surgery ( Johann-Wolfgang-Goethe University Hospital , Frankfurt am Main , Germany )

1984 - 1988

German Doctorate title ( ? PhD, Johann-Wolfgang-Goethe University , Frankfurt am Main , Germany )

1996 - 1997

Postgraduate Research & Training, ( T.U. Munchen University Hospital , M.H. Hannover University Hospital , J.W. Goethe University Hospital )


Work experience

1990 - Today

Lecturer, Assistant Professor, Associate Professor of Surgery in Department of Surgery, University of Ioannina , Greece .


  Scientific Research Activity
1984 - 1999
Clinical Research and Practice based on traditional biology, genetics and medicine

2000 - 2006

Reductionist genetics and molecular biology based on single genes or single components of a system of interest.

2007 - 2012

Shifting from reductionist to systems science, genome architecture and personalized medicine.
Protein-protein interactions and signal transduction interactions network (interactome), gene-gene interactions, molecular networks, dynamics of genome-lifestyle network.

2012 Scientific Director and co-founder of the ?Center of Biosystems & Synthetic Genomic Network Medicine? at Ioannina University.

Stepwise progress from Traditional Research to Precision Oncology

Scientific Research area



1985 – 2006




2001 – Today

Personalized Cancer Medicine: Combination of clinico-pathologic and single – gene mutated/amplified genes. Prophylactic and therapeutic surgery for hereditary cancer syndromes, targeted drugs



2007 – Today

Molecular interaction networks



2008 – 2011

Genome-Wide Association Studies (GWAS)



2010 – Today

Precision Cancer Medicine: Static and Spatiotemporal genome analysis with conventional and breakthrough NGS systems. Intratumor heterogeneity (MR-NGS, single-cell DNA/RNA seq), serial cfDNA-NGS, comprehensive intra-patient heterogeneity, coding and non-coding genomic and transcriptional heterogeneity. Integration of Hi-C and CRISPR-Cas9 for understanding regulatory networks and future development of non-linear transcriptional network-based next-generation drugs.






BREAKTHROUGH proposed concepts - models
New concept of D2 gastrectomy effectiveness on gastric cancer.
Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery. 1998 May;123(5):573-8.
Novel clinico-genome model of non-linear genotype - phenotype map on exact prediction of individualized drug resistance and relapse.
Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn. 2010 Jan;10(1):33-48. doi: 10.1586/erm.09.69. Review.
New intra-patient genomic heterogeneity concept: Translational implications.
a. Roukos DH. Spatiotemporal Diversification of Intrapatient Genomic Clones and Early Drug Development Concepts Realize the Roadmap of Precision Cancer Medicine. Drug Discov Today. 2017 Aug; 22(8): 1148-1164. doi: 10.1016/ j.drudis.2017.03.014.

b. Kyrochristos ID, Glantzounis GK, Goussia A, Eliades A , Achilleos A, Tsangaras K , Hadjidemetriou I, Elpidorou M, Ioannides M, Koumbaris G,Mitsis M, Patsalis P. C. ,Roukos DH. Proof-of-concept pilot study on comprehensive spatiotemporal intra-patient heterogeneity for colorectal cancer with liver metastasis.


i) Evaluator of research projects with both remote evaluation and active participation in consensus meetings
1. Evaluator in EU research projects (Health-FP7-INNOVATION-1-2-Systems Medicine and Personalized Medicine (2011, 2012, Experts panel consensus meetings, Brussels ) and Horizon 2020
2. Evaluator in France "Agence Nationale de la Recherche" (ANR) research projects (Equipex 2011 ANR 2 Experts panel consensus meetings, Paris 20-21 Sept., and 30 Nov.-2 Dec. 2011), and 4 projects of " Institut National de la Sant? et de la Recherche M?dicale" (INSERM) of 'Physique-Cancer' Program.
3. Evaluator in Italy [Ministry for Education University and Research (MIUR)].

ii) Remote evaluation - Reviewer of national research projects Reviewer (with honorarium): Research projects from European countries (UK, Italy, The Netherlands) and Asian countries (Singapore, Taiwan, Hong-Kong).

Journals Reviewer
Reviewer in high-impact journals (Nature Biotechnology, Nature Reviews Genetics, Lancet Oncology [honorarium for fast-track articles], Nature Reviews Clinical Oncology, Nature Communications, Nature Protocols) and multiple other journals.
  Editorial Board Member
  Organazing Committee Member
  Invited Speaker in international meetings
  International recognition. Leading Expert

Assessment criteria



  PubMed (MEDLINE) ISI web of Knowledge Scopus
Publications 255 265 295
Citations NA 9017 9886
Hirsch (h-factor) NA 71 78

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 15 July 2021